Journal profile · ONCOLOGY
NEOPLASIA
ISSN 1476-5586 · Neoplasia Press · UNITED STATES
NEOPLASIA: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.8; fully open access; APC about USD 3,790; median 68 days to acceptance (90 articles, last 24 months); 137 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
NEOPLASIA is published by Neoplasia Press and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer, Hypoxia, and Metabolism, Cancer-related Molecular Pathways and Cancer Cells and Metastasis, together about 21.6% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Neoplasia publishes the results of novel investigations in all areas of oncology research. The title Neoplasia was chosen to convey the journal’s breadth, which encompasses the traditional disciplines of cancer research as well as emerging fields and interdisciplinary investigations. Neoplasia is interested in studies describing new molecular and genetic findings relating to the neoplastic phenotype and in laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment. In addition to regular Research Reports, Neoplasia also publishes Reviews and Meeting Reports. Neoplasia is committed to ensuring a thorough, fair, and rapid review and publication schedule to further its mission of serving both the scientific and clinical communities by disseminating important data and ideas in cancer research.Neoplasia encourages the free exchange of all clones, cell lines, and biological reagents described in its pages to facilitate the progress of research in order to ultimately provide those fighting neoplastic diseases with new diagnostic, preventative and therapeutic options.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief A. RehemtullaPublisher website
Editorial board by country: 2 in mainland China (about 13%); most named India 5, United States 4, Mainland China 2, United Kingdom 2, Spain 1 (15 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology7.7%
- Cancer-related Molecular PathwaysMedicine7.1%
- Cancer Cells and MetastasisMedicine6.7%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology6.4%
- Angiogenesis and VEGF in CancerBiochemistry, Genetics and Molecular Biology5.1%
- Prostate Cancer Treatment and ResearchMedicine4.4%
- Ubiquitin and proteasome pathwaysBiochemistry, Genetics and Molecular Biology4.3%
- Glioma Diagnosis and TreatmentMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.8LetPub ·
- Impact factor (publisher)
- 4.8Publisher website ·
- CiteScore 2026-06
- 11.4LetPub ·
- CiteScore (publisher)
- 11.4Publisher website ·
- SJR 2026-06
- 2.28LetPub ·
- SNIP 2026-06
- 1.73LetPub ·
- h-index
- 115LetPub ·
- h-index
- 160OpenAlex ·
- i10-index
- 2,351OpenAlex ·
- 2-year mean citedness
- 5.07OpenAlex ·
- Self-citation rate
- 2.1%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 127LetPub ·
Articles by year OpenAlex count · 2,931 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 99 | 99 | 91 |
| 2025 | 137 | 137 | 580 |
| 2024 | 151 | 151 | 1,292 |
| 2023 | 83 | 83 | 1,420 |
| 2022 | 92 | 92 | 4,857 |
| 2021 | 106 | 106 | 2,788 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
68 daysMedian, submission to acceptance · P25–P75 45 days – 125 days
- Acceptance to online
- median 8 days (90 articles)
- Submission to online
- median 78 days
- Sample
- 90 articles with submission and acceptance dates (318 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to first decision
- 3 daysPublisher website ·
- First decision after review
- 57 daysPublisher website ·
- Submission to acceptance
- 80 daysPublisher website ·
- Acceptance to publication
- 9 daysPublisher website ·
- Submission to publication (journal-reported)
- about 13 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,790 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,530 / EUR 3,300 / GBP 2,830 / JPY 437,830 | — | — | |
| LetPub | USD 3,170 | Yes | — | |
| Publisher website | USD 3,940 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers3, by deadline
Publisher websiteWhat to prepare2 items from the author guidelines
- Abstract
- ≤ 250 words
- Manuscript length
- ≤ 4,500 words
Article types accepted14, with length limits
- commentariesCommentaries are short articles that highlight one or several research papers published in a recent issue of the Journal, placing the results in context for the…Length not stated
- commentaryibutions are not considered. Mechanics: Commentaries have a limit of 1,500 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,500 words · references ≤ 10
- editorialsEditorials serve as the voice of Neoplasia and are written by the Journal's Editors and Guest Editors.Length not stated
- lettercted and invited to respond. Mechanics: Letters have a limit of 1,000 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,000 words · references ≤ 10
- letters to the editorsLetters to the Editors which comment directly on work that has previously been published in the Journal will be considered.Length not stated
- opinionthout any published support. Mechanics: Opinion articles have a limit of 2,500 words and no more than 60 references. Authors are asked to limitmain text ≤ 2,500 words · references ≤ 60
- opinion articleOpinions may reflect an individual perception, involvement, or contribution to oncology, and should be prepared in a similar way to a Review.Length not stated
- original research articles and Methods, Results and Discussion). Original research articles have a limit of 4,500 words and no more than 50 references. Authors are asked to limitmain text ≤ 4,500 words
- perspectivenbox: neoplasia@elsevier.com Mechanics: Perspectives have a limit of 1,200 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,200 words · references ≤ 10
- perspectivesPerspectives are short pieces that aim to highlight for a very broad audience a significant recent development in the field or to raise awareness about a topic …Length not stated
- reviewtroduction, discussion, and conclusion. Reviews have a limit of 4,500 words and no more than 80 references. Authors are asked to limitmain text ≤ 4,500 words · references ≤ 80
- review articleReview articles offer a balanced account of newly emerging or rapidly progressing fields and provide a guide to the most relevant recent literature and prospect…main text ≤ 4,500 words · references ≤ 80
- short communicationSpotlights Spotlights are short articles intended to provide a quick update on one or two recent research articles published in other journals that signify a ma…main text ≤ 1,500 words · references ≤ 10
- spotlightsSpotlights are short articles intended to provide a quick update on one or two recent research articles published in other journals that signify a major advance…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Publishing ethics policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Neoplasia Press
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 1476-5586
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about NEOPLASIA
What CAS zone is NEOPLASIA in?
In the 2025 upgraded edition of the CAS Journal Ranking, NEOPLASIA is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of NEOPLASIA?
The latest impact factor listed by LetPub is 4.8; CiteScore 11.4, h-index 160.
How long does peer review take at NEOPLASIA?
Based on the dates recorded on 90 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 68 days (interquartile range 45–125 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of NEOPLASIA?
According to the journal's author guidelines: Abstract: ≤ 250 words; Manuscript length: ≤ 4,500 words. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of NEOPLASIA based?
Of the 15 board members whose country the journal's board page names, 2 (about 13%) are in mainland China; the countries named most often are India (5), United States (4) and Mainland China (2). Counted from the institutions listed on the board page; for reference only.
Which databases index NEOPLASIA?
According to LetPub and DOAJ records, NEOPLASIA is indexed in SCIE, Scopus and DOAJ.
Is NEOPLASIA open access, and what is the APC?
NEOPLASIA is a fully open-access journal. APC about USD 3,790.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-28). Last updated: .